You are now leaving www.klisyrihcp.com

You are now leaving KlisyriHCP.com and will be directed to an independent, third-party website. The Privacy Policy and the Terms of Use of the destination website will apply.

OK

Klisyri® Has An Established Safety And Tolerability Profile1

MOST LSRs WERE MILD TO MODERATE1
table showing Klisyri local skin reponse rates

Adverse Reactions Occurring in ≥2% of Subjects in 2 Controlled Clinical Trials (Pooled Safety Population)1

table showing Klisyri adverse reaction rates

*

Application site pain includes pain, tenderness, stinging, and burning sensation at the application site.

teal bullet point

No patients withdrew from the trials due to adverse reactions1

VISUAL ASSESSMENT OF LSRs2,3

TAP TO ENLARGE

SCALP

TAP TO ENLARGE

FACE

TAP TO ENLARGE

FACE

teal bullet point

Clinical studies in healthy subjects demonstrated KLISYRI® did not cause contact sensitization (n=261), phototoxic skin reactions (n=31), or photoallergic skin reactions (n=64)1

teal bullet point

The mean LSR composite score after treatment with KLISYRI® peaked on day 8, rapidly decreased by day 15, and resolved by day 292,3

LSRs were assessed using a grading scale: 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The LSR composite score was the sum of the grades of LSRs at each visit (0 to 18).1
LSRs: local skin reactions.

Important Safety Information

Indication

KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.

Important Safety Information

Warnings and Precautions

Ophthalmic Adverse Reactions

KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.

Local Skin Reactions

Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment. Occlusion after topical application of KLISYRI is more likely to result in irritation.

Adverse Reactions

The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.

Please see full Prescribing Information.

To report an adverse event or product complaint, call or email: Medical Affairs and Customer Relations • Phone: 1-866-665-2782 • Fax: 510-595-8183 • Email: almirallmc@eversana.com

Important Safety Information

Indication

KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.

Important Safety Information

Warnings and Precautions

Ophthalmic Adverse Reactions

KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.

Local Skin Reactions

Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment. Occlusion after topical application of KLISYRI is more likely to result in irritation.

Adverse Reactions

The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.

Please see full Prescribing Information.

To report an adverse event or product complaint, call or email: Medical Affairs and Customer Relations • Phone: 1-866-665-2782 • Fax: 510-595-8183 • Email: almirallmc@eversana.com

References:

1. KLISYRI [package insert]. Exton, PA: Almirall, LLC, 2020. 2. Data on file. 2019. KX01-AK-004. 3. Data on file. 2019. KX01-AK-003.

Almirall logo

KLISYRI® is a registered trademark of Almirall, LLC. © Copyright 2005-2021. All Rights Reserved. Almirall, LLC, Exton, PA 19341 US-TIRBA-2100057 02/2021

Klisyri logo

Sign Up

Information Request

Qualified U.S. healthcare professionals who are practicing medicine in the U.S. are invited to register, should they wish to receive information about KLISYRI®.

Terms and Conditions

Your submission of this Information Request form constitutes your specific request to receive ongoing email communications, including marketing communications and messages, from KLISYRI® and Almirall, LLC. You may opt out from such email communication at any time by following the "Unsubscribe" link and/or instructions included in the confirmation email you will receive as a result of this request.

By submission of this form, you affirm that you are a licensed healthcare professional eligible to practice in at least one state in the U.S. By submission of this form, you further agree to the terms and conditions set forth in the Almirall, LLC Privacy Policy page, available by clicking on the link at the bottom of this page.

*Required fields.
Submitting...

KLISYRI® is a registered trademark of Almirall, LLC. © Copyright 2005-2021. All Rights Reserved. Almirall, LLC, Exton, PA 19341 US-TIRBA-2100057 02/2021

Klisyri logo

Thank You For Signing Up!

You are now enrolled to receive news and updates about KLISYRI® (tirbanibulin) ointment. Please look for a welcome email that will be sent to .